2011

Optimization and evaluation of cyclosporine A nanosuspension stabilized by combination stabilizers using high pressure homogenization method

The purpose of this study was to develop Cyclosporine A (CsA) nanosuspension by using different stabilizers for oral administration. CsA nanosuspension was prepared by high pressure homogenization technology and HPMC and Soluplus® combination were selected as stabilizers. After Design of Experiment (DoE) analysis, optimum formulation was selected and characterized by particle size (PS), particle size distribution (PDI) and zeta potential (ZP) measurements. Scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (X-RD), and fourier transform infrared (FTIR) analysis were also performed. Solubility studies were done with optimum lyophilised CsA nanosuspension. The results revealed that appropriate PS, PDI, and ZP results were not obtained with the use of stabilizers separately in preformulation studies. Optimum stabilizers ratio was determined CsA:HPMC:Soluplus® 1:1:0.5 (w/w) in nanosuspension formulation after DoE. It was found to be appropriate with a small particle size of 366.8 ± 9.6 nm, a narrow particle size distribution of 0.48 ± 0.02, and a negative zeta potential value of -14.4 ± 0.4 mV after 30 homogenization cycles. In solubility study, the CsA solubility in the nanosuspension was increased up to 2.1 times in comparison with the coarse CsA. CsA nanosuspension showed a short-term stability over the examined period of one month. CsA nanosuspension can be successfully produced by Microfluidics with HPMC:Soluplus® combination as stabilizers using DoE approach

PDF

___

Guada M, Beloqui A, Kumar MNVR, Carmen Dios-Viéitez VPM, Blanco-Prieto MJ. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy. J Control Release. 2016; 225: 269–282. [CrossRef]
Survase SA, Kagliwal LD, Annapure US, Singhal RS. Cyclosporin A — A review on fermentative production, downstream processing and pharmacological applications. Biotechnol Adv. 2011; 29: 418–435. [CrossRef]
Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008; 355: 321–327. [CrossRef]
Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm. 2006; 317: 82–89. [CrossRef]
Möschwitzer J, Müller RH. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm. 2006; 62: 282–287. [CrossRef]
Wang GD, Mallet FP, Ricard F, Heng JYY. Pharmaceutical nanocrystals. Curr Opin Chem Eng. 2012; 1(2): 102-107. [CrossRef]
Gülsün T, Gürsoy RN, Öner L. Nanocrystal technology for oral delivery of poorly water-soluble drugs. FABAD J Pharm Sci. 2009; 34(1): 55-65.
Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008; 3(3): 295-309. [CrossRef]
Santos AM, Carvalho FC, Teixeira DA, Azevedo DL, Barros WM, Gremião MPD. Computational and experimental approaches for development of methotrexate nanosuspensions by bottom-up nanoprecipitation. Int J Pharm. 2017; 524: 330–338. [CrossRef]
Du J, Li X, Zhao H, Zhou Y, Wang L, Tian S, Wang Y. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies. Int J Pharm. 2015; 495: 738-749. [CrossRef]
Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. Eur J Pharm Sci. 2018; 122: 254–263. [CrossRef]
Karakucuk A, Celebi N, Teksin ZS. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Eur J Pharm Sci. 2016; 95: 111–121. [CrossRef]
Verma S, Lan Y, Gokhale R, Burgess JR. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm. 2009; 377: 185-198. [CrossRef]
Fernandes AR, Ferreira NR, Fangueiro JF, Santos AC, Veiga FJ, Cabral C, Silva AM, Souto EB. Ibuprofen nanocrystals developed by 22 factorial design experiment: A new approach for poorly water-soluble drugs. Saudi Pharm J. 2017; 25: 1117–1124. [CrossRef]
Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011; 413; 194– 201. [CrossRef]
Möschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004; 58: 615–619. [CrossRef]
Li Y, Wang D, Lu S, Zeng L, Wang Y, Song W, Liu J. Pramipexole nanocrystals for transdermal permeation: Characterization and its enhancement micro-mechanism. Eur J Pharm Sci. 2018; 124: 80-88. [CrossRef]
Medarević D, Djuriš J, Ibrić S, Mitrić M, Kachrimanis K. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. Int J Pharm. 2018; 540: 150–161. [CrossRef]
Huang S, Zhang Q, Li H, Sun Y, Cheng G, Zou M, Piao H. Increased bioavailability of efonidipine hydrochloride nanosuspensions by the wet-milling method. Eur J Pharm Biopharm. 2018; 130: 108–114. [CrossRef]
Toziopoulou F, Malamatari M, Nikolakakis I, Kachrimanis K. Production of aprepitant nanocrystals by wet media milling and subsequent solidification. Int J Pharm. 2017; 533: 324–334. [CrossRef]
Sharma OP, Patel V, Mehta T. Design of experiment approach in development of febuxostat nanocrystal: Application of Soluplus® as stabilizer. Powder Technol. 2016; 302: 396–405. [CrossRef]
Kumar S, Xu X, Gokhale R, Burgess DJ. Formulation parameters of crystalline nanosuspensions on spray drying processing: A DoE approach. Int J Pharm. 2014; 464: 34–45. [CrossRef]
Guo C, Chen Y, Zhu J, Wang J, Xu Y, Luan H, Zhu Z, Hu M, Wang H. Preparation, optimization of intravenous ZL004 nanosuspensions by the precipitation method, effect of particle size on in vivo pharmacokinetics and tissue distribution. J Drug Deliv Sci Technol. 2019; 50: 313–320. [CrossRef]
Lu Y, Wang Z, Li T, McNally H, Park K, Sturek M. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. J Control Release. 2014; 176: 76–85. [CrossRef]
Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011; 415: 293– 300. [CrossRef]
Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, Cui. Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010; 40: 325–334. [CrossRef]
Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013; 453: 142– 156. [CrossRef]
Salazar J, Müller RH, Möschwitzer JP. Performance comparison of two novel combinative particle-size-reduction technologies. J Pharm Sci. 2013; 102 (5): 1636-1649. [CrossRef]
Salazar J, Ghanem A, Müller RH, Möschwitzer JP. Nanocrystals: Comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur J Pharm Biopharm. 2012; 81: 82–90. [CrossRef]
Shegokar R, Müller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010; 399: 129–139. [CrossRef]
Gulsun T, Borna SE, Vural I, Sahin S. Preparation and characterization of furosemide nanosuspensions. J Drug Deliv Sci Technol. 2018; 45: 93–100. [CrossRef]
Zong L, Li X, Wang H, Cao Y, Yin L, Li M, Wei Z, Chen D, Pu X, Han J. Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycolpoly(β-Benzyl-l-aspartate) (PEG-PBLA). Int J Pharm. 2017; 531: 108–117. [CrossRef]
Attari Z, Bhandari A, Jagadish PC, Lewis S. Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology. Saudi Pharm J. 2016; 24: 57–63. [CrossRef]
Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: An in vitro and in vivo evaluation. Int J Pharm. 2014; 477: 251–260. [CrossRef]
Sinha B, Müller RH, Moschwitzer JP. Systematic investigation of the cavi-precipitation process for the production of ibuprofen nanocrystals. Int J Pharm. 2013; 458: 315– 323. [CrossRef]
Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006; 62: 3–16. [CrossRef]
Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. J Control Release. 2013; 172: 1126–1141. [CrossRef]
He J, Han Y, Xu G, Yin L, Neubi MN, Zhou J, Ding Y. Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement. RSC Adv. 2017; 7: 13053–13064. [CrossRef]
Yue PF, Li Y, Wan J, Yang M, Zhu WF, Wang CH. Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property. Int J Pharm. 2013; 454: 269– 277. [CrossRef]